I. Kusters

发表

Immunogenicity of Unadjuvanted and AF03-Adjuvanted A/H1N1/California/07/2009 Influenza Vaccines in Naïve and Influenza-Primed Mice

Marie-Clotilde Bernard, Catherine Caillet, F. Vogel, 2011 .

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

C. Moste, Marie-Clotilde Bernard, Catherine Caillet, 2010, Vaccine.

Emulsion-based adjuvants for influenza vaccines

J. Haensler, Catherine Caillet, F. Vogel, 2009, Expert review of vaccines.

p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.

C. Harris, M. Hollstein, M. Marion, 1994, Carcinogenesis.

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

T. Vesikari, Stéphanie Pépin, M. Denis, 2012, Human vaccines & immunotherapeutics.

Manufacturing Vaccines for an Emerging Viral Infection–Specific Issues Associated with the Development of a Prototype SARS Vaccine

J. Saluzzo, I. Kusters, J. Matthews, 2009, Vaccines for Biodefense and Emerging and Neglected Diseases.

Evaluation of SARS-Coronavirus Decontamination Procedures

J. Saluzzo, V. Lecouturier, C. Lutsch, 2007 .

p53 mutation and protein accumulation during multistage human esophageal carcinogenesis.

R. Metcalf, M. Hollstein, D. Lane, 1992, Cancer research.

Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes

J. Honnorat, D. Aunis, M. Mattei, 1999, The European journal of neuroscience.

The C-Terminal Region but Not the Arg-X-Pro Repeat of Epstein-Barr Virus Protein EB2 Is Required for Its Effect on RNA Splicing and Transport

M. Buisson, A. Sergeant, I. Kusters, 1999, Journal of Virology.

Mechanisms behind TB, HBV, and HIV chronic infections.

T. Ottenhoff, N. Manel, D. Durantel, 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

G. Leroux-Roels, K. Hoppenbrouwers, I. Leroux-Roels, 2008, The Journal of infectious diseases.

Screening for p53 Gene Mutations in Archived Tumors of Workers Occupationally Exposed to Carcinogens: Examples from Analysis of Bladder Tumors

T. Sørlie, P. Vineis, M. Hollstein, 1995, Journal of occupational and environmental medicine.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

G. Leroux-Roels, K. Hoppenbrouwers, I. Leroux-Roels, 2008, The Journal of infectious diseases.